The Role of Cathelicidin LL-37 in Cancer Development

Archivum Immunologiae et Therapiae Experimentalis

Volumn 64, Issue 1, 2016, Pages 33-46

  Piktel, Ewelina ^a   Niemirowicz, Katarzyna ^a   Wnorowska, Urszula ^a   Wątek, Marzena ^b   Wollny, Tomasz ^b   Głuszek, Katarzyna ^b   Góźdź, Stanisław ^c   Levental, Ilya ^d   Bucki, Robert ^a,e  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Center Holy Cross Regional Hospital   (Poland)

^c The University of Texas Medical School ^*  (Poland)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e Pathophysiology and Microbiology of Infections   (Poland)

Author keywords

Cancer; Carcinogenesis; Cathelicidin; Immune system; LL 37

Indexed keywords

CASPASE; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CPG OLIGODEOXYNUCLEOTIDE; INTERLEUKIN 32; MITOGEN ACTIVATED PROTEIN KINASE; PROTEASOME; PROTEIN P42; PROTEIN P44; SOMATOMEDIN C RECEPTOR; TELOMERASE; ANTIMICROBIAL CATIONIC PEPTIDE; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER TISSUE; CARCINOGENESIS; CELL DEATH; COLON CANCER; DISEASE COURSE; DOWN REGULATION; ENZYME ACTIVATION; HELICOBACTER INFECTION; HUMAN; IMMUNITY; LEUKEMIA; LUNG CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MESENCHYMAL STEM CELL; NEOPLASM; NONHUMAN; OVARY CANCER; PATHOPHYSIOLOGY; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; UPREGULATION; ANIMAL; ANTIBODY SPECIFICITY; CELL GROWTH; GENE EXPRESSION REGULATION; IMMUNOLOGY; IMMUNOMODULATION; INNATE IMMUNITY;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; CARCINOGENESIS; CELL GROWTH PROCESSES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNITY, INNATE; IMMUNOMODULATION; ORGAN SPECIFICITY; SIGNAL TRANSDUCTION;

EID: 84954362778     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-015-0359-5     Document Type: Review

References (108)

1. Agerberth B, Charo J, Werr J et al (2000) The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood 96:3086–3093
2. Alzahrani S, Lina TT, Gonzalez J et al (2014) Effect of Helicobacter pylori on gastric epithelial cells. World J Gastroenterol 20:12767–12780
3. An LL, Ma XT, Yang YH et al (2005) Marked reduction of LL-37/hCAP-18, an antimicrobial peptide, in patients with acute myeloid leukemia. Int J Hematol 81:45–47
4. Anand P, Kunnumakkara AB, Sundaram C et al (2008) Cancer is a preventable disease that requires major lifestyle changes. Pharm Res 25:2097–2116
5. Armogida SA, Yannaras NM, Melton AL et al (2004) Identification and quantification of innate immune system mediators in human breast milk. Allergy Asthma Proc 25:297–304
6. Arnoult D, Gaume B, Karbowski M et al (2003) Mitochondrial release of AIF and EndoG requires caspase activation downstream of Bax/Bak-mediated permeabilization. EMBO J 22:4385–4399
7. Bals R, Wang X, Zasloff M et al (1998) The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci USA 95:9541–9546
8. Barlow PG, Svoboda P, Mackellar A et al (2011) Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS One 6:e25333
9. Bartek J, Lukas J (2001) Pathways governing G1/S transition and their response to DNA damage. FEBS Lett 490:117–122
10. Bucki R, Janmey PA (2006) Interaction of the gelsolin-derived antibacterial PBP 10 peptide with lipid bilayers and cell membranes. Antimicrobial Agents Chemother 50:2932–2940
11. Bucki R, Pastore JJ, Randhawa P et al (2004) Antibacterial activities of rhodamine B-conjugated gelsolin-derived peptides compared to those of the antimicrobial peptides cathelicidin LL37, magainin II, and melittin. Antimicrobial Agents Chemother 48:1526–1533
12. Bucki R, Byfield FJ, Janmey PA (2007) Release of the antimicrobial peptide LL-37 from DNA/F-actin bundles in cystic fibrosis sputum. Eur Respir J 29:624–632
13. Bucki R, Namiot DB, Namiot Z et al (2008) Salivary mucins inhibit antibacterial activity of the cathelicidin-derived LL-37 peptide but not the cationic steroid CSA-13. J Antimicrob Chemother 62:329–335
14. Bucki R, Leszczynska K, Namiot A et al (2010) Cathelicidin LL-37: a multitask antimicrobial peptide. Arch Immunol Ther Exp 58:15–25
15. Byfield FJ, Kowalski M, Cruz K et al (2011) Cathelicidin LL-37 increases lung epithelial cell stiffness, decreases transepithelial permeability, and prevents epithelial invasion by Pseudomonas aeruginosa. J Immunol 187:6402–6409
16. Castells M, Milhas D, Gandy C et al (2013) Microenvironment mesenchymal cells protect ovarian cancer cell lines from apoptosis by inhibiting XIAP inactivation. Cell Death Dis 4:e887
17. Chen PM, Yen ML, Liu KJ et al (2011) Immunomodulatory properties of human adult and fetal multipotent mesenchymal stem cells. J Biomed Sci 18:49
18. Cheng M, Ho S, Yoo JH et al (2014) Cathelicidin suppresses colon cancer development by inhibition of cancer associated fibroblasts. Clin Exp Gastroenterol 8:13–29
19. Choi KY, Napper S, Mookherjee N (2014) Human cathelicidin LL-37 and its derivative IG-19 regulate interleukin-32-induced inflammation. Immunology 143:68–80
20. Chuang CM, Monie A, Wu A et al (2009) Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer. Hum Gene Ther 20:303–313
21. Clendenen TV, Lundin E, Zeleniuch-Jacquotte A et al (2011) Circulating inflammation markers and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 20:799–810
22. Coffelt SB, Waterman RS, Florez L et al (2008) Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. Int J Cancer 122:1030–1039
23. Coffelt SB, Marini FC, Watson K et al (2009) The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc Natl Acad Sci USA 106:3806–3811
24. Cohen S, Bruchim I, Graiver D et al (2013) Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2. J Mol Med 91:357–368
25. Currie SM, Findlay EG, McHugh BJ et al (2013) The human cathelicidin LL-37 has antiviral activity against respiratory syncytial virus. PLoS One 8:e73659
26. Dinarello CA, Kim SH (2006) IL-32, a novel cytokine with a possible role in disease. Ann Rheum Dis 65(Suppl 3):iii61–iii64
27. Donato AL, Huang Q, Liu X et al (2014) Caspase 3 promotes surviving melanoma tumor cell growth after cytotoxic therapy. J Invest Dermatol 134:1686–1692
28. Dosler S, Karaaslan E (2014) Inhibition and destruction of Pseudomonas aeruginosa biofilms by antibiotics and antimicrobial peptides. Peptides 62:32–37
29. Felaco P, Castellani ML, De Lutiis MA et al (2009) IL-32: a newly-discovered proinflammatory cytokine. J Biol Regul Homeost Agents 23:141–147
30. Ferrari D, Pizzirani C, Adinolfi E et al (2006) The P2X7 receptor: a key player in IL-1 processing and release. J Immunol 176:3877–3883
31. Folini M, Gandellini P, Zaffaroni N (2009) Targeting the telosome: therapeutic implications. Biochim Biophys Acta 1792:309–316
32. Frohm M, Agerberth B, Ahangari G et al (1997) The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J Biol Chem 272:15258–15263
33. Galluzzi L, Joza N, Tasdemir E et al (2008) No death without life: vital functions of apoptotic effectors. Cell Death Differ 15:1113–1123
34. Gao P, Zhao H, You J et al (2014) Association between interleukin-8 -251A/T polymorphism and risk of lung cancer: a meta-analysis. Cancer Invest 32:518–525
35. Girnita A, Zheng H, Grönberg A et al (2012) Identification of the cathelicidin peptide LL-37 as agonist for the type I insulin-like growth factor receptor. Oncogene 31:352–365
36. Hase K, Murakami M, Iimura M et al (2003) Expression of LL-37 by human gastric epithelial cells as a potential host defense mechanism against Helicobacter pylori. Gastroenterology 125:1613–1625
37. Heilborn JD, Nilsson MF, Jimenez CI et al (2005) Antimicrobial protein hCAP18/LL-37 is highly expressed in breast cancer and is a putative growth factor for epithelial cells. Int J Cancer 114:713–719
38. Hensel JA, Chanda D, Kumar S et al (2011) LL-37 as a therapeutic target for late stage prostate cancer. Prostate 71:659–670
39. Huang Q, Li F, Liu X et al (2011) Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med 17:860–866
40. Hurtado P, Peh CA (2010) LL-37 promotes rapid sensing of CpG oligodeoxynucleotides by B lymphocytes and plasmacytoid dendritic cells. J Immunol 184:1425–1435
41. Ishigami S, Arigami T, Uchikado Y et al (2013) IL-32 expression is an independent prognostic marker for gastric cancer. Med Oncol 30:472
42. Jana J, Kar RK, Ghosh A et al (2013) Human cathelicidin peptide LL37 binds telomeric G-quadruplex. Mol BioSyst 9:1833–1836
43. Joosten LA, Netea MG, Kim SH et al (2006) IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA 103:3298–3303
44. Khandwala HM, McCutcheon IE, Flyvbjerg A et al (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21:215–244
45. Kim JE, Kim HJ, Choi JM et al (2010) The antimicrobial peptide human cationic antimicrobial protein-18/cathelicidin LL-37 as a putative growth factor for malignant melanoma. Br J Dermatol 163:959–967
46. Kim HJ, Hwang SW, Kim N et al (2014) Helicobacter pylori and molecular markers as prognostic indicators for gastric cancer in Korea. J Cancer Prev 19:56–67
47. Koczulla R, von Degenfeld G, Kupatt C et al (2003) An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 111:1665–1672
48. Koensgen D, Bruennert D, Ungureanu S et al (2015) Polymorphism of the IL-8 gene and the risk of ovarian cancer. Cytokine 71:334–338
49. Korhonen R, Moilanen E (2014) Mitogen-activated protein kinase phosphatase 1 as an inflammatory factor and drug target. Basic Clin Pharmacol Toxicol 114:24–36
50. Krętowski R, Stypułkowska A, Cechowska-Pasko M (2015) Efficient apoptosis and necrosis induction by proteasome inhibitor: bortezomib in the DLD-1 human colon cancer cell line. Mol Cell Biochem 398:165–173
51. −/−. Oncol Rep 28:829–834
52. Kuroda K, Fukuda T, Okumura K et al (2013) Ceragenin CSA-13 induces cell cycle arrest and antiproliferative effects in wild-type and p53 null mutant HCT116 colon cancer cells. Anticancer Drugs 24:826–834
53. Lee S, Kim JH, Kim H et al (2011) Activation of the interleukin-32 pro-inflammatory pathway in response to human papillomavirus infection and over-expression of interleukin-32 controls the expression of the human papillomavirus oncogene. Immunology 132:410–420
54. Leszczynska K, Namiot D, Byfield FJ et al (2013) Antibacterial activity of the human host defence peptide LL-37 and selected synthetic cationic lipids against bacteria associated with oral and upper respiratory tract infections. J Antimicrob Chemother 68:610–618
55. Levine B, Abrams J (2008) p53: the Janus of autophagy? Nat Cell Biol 10:637–639
56. Li X, Li Y, Han H et al (2006) Solution structures of human LL-37 fragments and NMR-based identification of a minimal membrane-targeting antimicrobial and anticancer region. J Am Chem Soc 128:5776–5785
57. Lim R, Lappas M, Riley C et al (2013) Investigation of human cationic antimicrobial protein-18 (hCAP-18), lactoferrin and CD163 as potential biomarkers for ovarian cancer. J Ovarian Res 6:5
58. López-García B, Lee PH, Yamasaki K et al (2005) Anti-fungal activity of cathelicidins and their potential role in Candida albicans skin infection. J Invest Dermatol 125:108–115
59. Macciò A, Madeddu C (2012) Inflammation and ovarian cancer. Cytokine 58:133–147
60. Mader JS, Mookherjee N, Hancock RE et al (2009) The human host defense peptide LL-37 induces apoptosis in a calpain- and apoptosis-inducing factor-dependent manner involving Bax activity. Mol Cancer Res 7:689–702
61. Mai CW, Kang YB, Pichika MR (2013) Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers. Onco Targets Ther 6:1573–1587
62. McSorley MA, Alberg AJ, Allen DS et al (2007) C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol 109:933–941
63. Mishra J, Drummond J, Quazi SH et al (2013) Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis. Crit Rev Oncol Hematol 86:232–250
64. Montreekachon P, Chotjumlong P, Bolscher JG et al (2011) Involvement of P2X(7) purinergic receptor and MEK1/2 in interleukin-8 up-regulation by LL-37 in human gingival fibroblasts. J Periodontal Res 46:327–337
65. Mookherjee N, Brown KL, Bowdish DM et al (2006) Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol 176:2455–2464
66. Muccioli M, Benencia F (2014) Toll-like Receptors in ovarian cancer as targets for immunotherapies. Front Immunol 5:341
67. Neidle S (2010) Human telomeric G-quadruplex: the current status of telomeric G-quadruplexes as therapeutic targets in human cancer. FEBS J 277:1118–1125
68. Netea MG, Azam T, Lewis EC et al (2006) Mycobacterium tuberculosis induces interleukin-32 production through a caspase-1/IL-18/interferon-gamma-dependent mechanism. PLoS Med 3:e277
69. Niemirowicz K, Prokop I, Wilczewska AZ et al (2015) Magnetic nanoparticles enhance the anticancer activity of cathelicidin LL-37 peptide against colon cancer cells. Int J Nanomedicine 10:3843–3853
70. Nold-Petry CA, Rudloff I, Baumer Y et al (2014) IL-32 promotes angiogenesis. J Immunol 192:589–602
71. Ostrand-Rosenberg S (2008) Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev 18:11–18
72. Ouyang L, Shi Z, Zhao S et al (2012) Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif 45:487–498
73. Overhage J, Campisano A, Bains M et al (2008) Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun 76:4176–4182
74. Peng LS, Zhuang Y, Li WH et al (2014) Elevated interleukin-32 expression is associated with Helicobacter pylori-related gastritis. PLoS One 9:e88270
75. Prevete N, Liotti F, Visciano C et al (2015) The formyl peptide receptor 1 exerts a tumor suppressor function in human gastric cancer by inhibiting angiogenesis. Oncogene 34:3826–3838
76. Ren SX, Cheng AS, To KF et al (2012) Host immune defense peptide LL-37 activates caspase-independent apoptosis and suppresses colon cancer. Cancer Res 72:6512–6523
77. Ren SX, Shen J, Cheng AS et al (2013) FK-16 derived from the anticancer peptide LL-37 induces caspase-independent apoptosis and autophagic cell death in colon cancer cells. PLoS One 8:e63641
78. Richardson PG, Mitsiades C, Hideshima T et al (2005) Proteasome inhibition in the treatment of cancer. Cell Cycle 4:290–296
79. Rico-Mata R, De Leon-Rodriguez LM, Avila EE (2013) Effect of antimicrobial peptides derived from human cathelicidin LL-37 on Entamoeba histolytica trophozoites. Exp Parasitol 133:300–306
80. Romero I, Bast RC (2012) Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology 153:1593–1602
81. Sakitani K, Hirata Y, Hayakawa Y et al (2012) Role of interleukin-32 in Helicobacter pylori-induced gastric inflammation. Infect Immun 80:3795–3803
82. Scott MG, Davidson DJ, Gold MR et al (2002) The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J Immunol 169:3883–3891
83. Shaykhiev R, Beisswenger C, Kändler K et al (2005) Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure. Am J Physiol Lung Cell Mol Physiol 289:L842–L848
84. Shioya M, Nishida A, Yagi Y et al (2007) Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease. Clin Exp Immunol 149:480–486
85. Sieprawska-Lupa M, Mydel P, Krawczyk K et al (2004) Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived proteinases. Antimicrob Agents Chemother 48:4673–4679
86. Simonsen DF, Farkas DK, Søgaard M et al (2014) Tuberculosis and risk of cancer: a Danish nationwide cohort study. Int J Tuberc Lung Dis 18:1211–1219
87. Sørensen OE, Follin P, Johnsen AH et al (2001) Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 97:3951–3959
88. Sorrentino C, Di Carlo E (2009) Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype. Am J Respir Crit Care Med 180:769–779
89. Steg AD, Burke MR, Amm HM et al (2014) Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer. Oncotarget 5:7065–7080
90. Takazawa Y, Kiniwa Y, Ogawa E et al (2014) Toll-like receptor 4 signaling promotes the migration of human melanoma cells. Tohoku J Exp Med 234:57–65
91. Tjabringa GS, Aarbiou J, Ninaber DK et al (2003) The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. J Immunol 171:6690–6696
92. Touboul C, Vidal F, Pasquier J et al (2014) Role of mesenchymal cells in the natural history of ovarian cancer: a review. J Transl Med 12:271
93. Travis SM, Anderson NN, Forsyth WR et al (2000) Bactericidal activity of mammalian cathelicidin-derived peptides. Infect Immun 68:2748–2755
94. Van Cutsem E, Geboes K (2007) The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer. Best Pract Res Clin Gastroenterol 21:1089–1108
95. Vandamme D, Landuyt B, Luyten W et al (2012) A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol 280:22–35
96. von Haussen Koczulla R, Shaykhiev RJ et al (2008) The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells. Lung Cancer 59:12–23
97. Wang G (2014) Human antimicrobial peptides and proteins. Pharmaceuticals 7:545–594
98. Weber G, Chamorro CI, Granath F et al (2009) Human antimicrobial protein hCAP18/LL-37 promotes a metastatic phenotype in breast cancer. Breast Cancer Res 11:R6
99. Wu WK, Cho CH, Lee CW et al (2010a) Proteasome inhibition: a new therapeutic strategy to cancer treatment. Cancer Lett 293:15–22
100. Wu WK, Sung JJ, To KF et al (2010b) The host defense peptide LL-37 activates the tumor-suppressing bone morphogenetic protein signaling via inhibition of proteasome in gastric cancer cells. J Cell Physiol 223:178–186
101. Wu WK, Wang G, Coffelt SB et al (2010c) Emerging roles of the host defense peptide LL-37 in human cancer and its potential therapeutic applications. J Int Cancer 127:1741–1747
102. Wu WK, Coffelt SB, Cho CH et al (2012) The autophagic paradox in cancer therapy. Oncogene 31:939–953
103. Yang De, Chen Q, Schmidt AP et al (2000) LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med 192:1069–1074
104. Yerlikaya A, Okur E, Baykal AT et al (2015) A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line. J Proteomics 113:315–325
105. Yousif NG, Al-Amran FG, Hadi N et al (2013) Expression of IL-32 modulates NF-κB and p38 MAP kinase pathways in human esophageal cancer. Cytokine 61:223–227
106. Zaiou M, Gallo RL (2002) Cathelicidins, essential gene-encoded mammalian antibiotics. J Mol Med 80:549–561
107. Zeng X, Yan T, Schupp JE et al (2007) DNA mismatch repair initiates 6-thioguanine—induced autophagy through p53 activation in human tumor cells. Clin Cancer Res 13:1315–1321
108. Zeng Q, Li S, Zhou Y et al (2014) Interleukin-32 contributes to invasion and metastasis of primary lung adenocarcinoma via NF-kappaB induced matrix metalloproteinases 2 and 9 expression. Cytokine 65:24–32